The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens
- 217 Downloads
Since drug candidates with low oral systemic exposure may be due to either or both absorption and metabolism factors, determining what factors limit the oral systemic exposure is not always obvious in a singlein-vivo pharmacokinetic (PK) assay. A rapid ratin-vivo PK screen where the oxidative drug metabolism has been attenuated using the suicide CYP450 inhibitor aminobenzotriazole (ABT) is described. We have shown that the roles of absorption and metabolism for drug candidates with low oral systemic exposure can be determined by comparing the PK parameters of drug candidates orally administered to non-treated and ABT-treated rats. Propranolol, metoprolol and climetidine are used as model drugs. Propranolol and metoprolol have low oral systemic exposures in rats primarily due to metabolism factors while the oral systemic exposure of climetidine is high in rats. For propranolol and metoprolol, large increases in the systemic exposure of these drugs were observed between non-treated and ABT-treated rats. ABT appeared not to increase or decrease significantly the rate and extent of absorption or metabolism of Cimetidine since that oral systemic exposure of non-treated and ABT-treated rats did not significantly change.
These experiments suggest that for drug candidates with low systemic exposures in rats an observation of no change in the oral systemic exposure in ABT-treated rats when compared to the non-treated rats imply that absorption (or formulation) factors limit the systemic exposure of the drug while an increase in the systemic exposure in ABT-treated rats imply that metabolism factors limit the systemic exposure. Due to the ease of preparing and interpreting PK data from ABT-treated rats, is suggested that this assay could be used as an alternative toin vivo cannulation assays. Please send reprint requests to: Dr G. W. Caldwell,
KeywordsCYP Suicide Inhibitors Drug Discovery Rat Pharmacokinetics ABT
Unable to display preview. Download preview PDF.
- 1.Caldwell, G. W. (2000). Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. [Published erratum appears in Curr Opin in Drug Discov Develop 2000, 3(2), 250]. Curr Opin in Drug Discov Devel 3(1), 30–41.Google Scholar
- 3.Caldwell, G. W.; Yan, Z.; Masucci, J. A.; Hageman, W.; Ritchie, D. M. (2003). Applied Pharmacokinetics in Drug Development. An Overview of Drug Discovery. Pharm Dev Regul 1(2), 117- 132.Google Scholar
- 7.Masucci, John A.; Caldwell, Gary W.; Jones, William J.; Juzwin, Stephen J.; Sasso, Patrick J.; Evangelisto, Mary. (2001). The use of on-line and off-line chromatographic extraction techniques coupled with mass spectrometry for support of in vivo and in vitro assays in drug discovery. Cur. Topics in Med Chem 1(5), 463–471.CrossRefGoogle Scholar
- 16.Meschter, C. L.; Mico, B. A.; Mortillo, M.; Feldman, D.; Garland, W. A.; Riley, J. A.; Kaufman, L. S. (1994). A 13-week toxicologic and pathologic evaluation of prolonged cytochromes P450 inhibition by 1-aminobenzotriazole in male rats. Fundamental and Applied Toxicology 22(3), 369–81.PubMedCrossRefGoogle Scholar
- 23.Shargel, L.; Yu, A.B.C. (1993). Applied Biopharmaceutical and Pharmacokinetics, 3rd Edition, Appleton and Lange, Stamford, CT.Google Scholar
- 24.Miller, J.C.; Miller, J.N. (1992). Statistics for analytical chemistry, 2nd Edition, Ellis Hardwood Limited, West Sussex, England.Google Scholar
- 25.Belpaire, F. M.; Smet, F. DE.; Vynckier, L. J.; Vermeiden, A. M.; Rosseel, M. T.; Bogaert, M. G.; Chauvelot-Moachon, L. (1990). Effect of aging on the pharmacokinetics of atenolol, metoprolol and propranolol in the rat. J Pharmacol Exp Therapeutics 254(1), 116–122.Google Scholar
- 27.Weiner, I.M.; Roth, L. ( 1981 ). Renal excretion of Cimetidine. J Pharmacol Exp Therapeutics 216(3), 516–520.Google Scholar
- 29.Griffiths, R.; Lewis, A.; Jeffrey, P. (1996). Models of drug absorption in situ and in conscious animals. Chapter 5 in Models for Assessing Drug Absorption and Metabolism, Eds. Borchardt, Smith and Wilson, Plenum Press, New York, page 67–82.Google Scholar